Cargando…

Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease

INTRODUCTION: Matrix metalloproteinases (MMP) are believed to be involved in the pathologic processes behind Alzheimer's disease (AD). In this study, we aimed to examine the cerebrospinal fluid (CSF) levels of MMPs and tissue inhibitors of metalloproteinase-1 (TIMP-1) in individuals with AD dem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stomrud, Erik, Björkqvist, Maria, Janciauskiene, Sabina, Minthon, Lennart, Hansson, Oskar
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919700/ https://www.ncbi.nlm.nih.gov/pubmed/20576109 http://dx.doi.org/10.1186/alzrt44

Ejemplares similares

The effect of white matter hyperintensities on statistical analysis of diffusion tensor imaging in cognitively healthy elderly and prodromal Alzheimer's disease
por: Svärd, Daniel, et al.
Publicado: (2017)

No Diagnostic Value of Plasma Clusterin in Alzheimer's Disease
por: Silajdžić, Edina, et al.
Publicado: (2012)

Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease
por: Björkqvist, Maria, et al.
Publicado: (2012)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's Disease
por: Westin, Karin, et al.
Publicado: (2012)

Cerebral Microbleeds and White Matter Hyperintensities in Cognitively Healthy Elderly: A Cross-Sectional Cohort Study Evaluating the Effect of Arterial Stiffness
por: Gustavsson, Anna-Märta, et al.
Publicado: (2015)

Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials
por: Borland, Emma, et al.
Publicado: (2022)

Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease
por: Buchhave, Peder, et al.
Publicado: (2009)

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
por: Silajdžić, Edina, et al.
Publicado: (2015)

Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis
por: Mattsson, Niklas, et al.
Publicado: (2016)

Tau Pathology and Parietal White Matter Lesions Have Independent but Synergistic Effects on Early Development of Alzheimer's Disease
por: Hertze, Joakim, et al.
Publicado: (2013)

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
por: Hertze, Joakim, et al.
Publicado: (2014)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET
por: van Westen, Danielle, et al.
Publicado: (2016)

A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2010)

β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly
por: Svenningsson, Anna L., et al.
Publicado: (2019)

Plasma tau levels in Alzheimer's disease
por: Zetterberg, Henrik, et al.
Publicado: (2013)

The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment
por: Borland, Emma, et al.
Publicado: (2020)

Involvement of Matrix Metalloproteinase-9 in Amyloid-β 1–42–Induced Shedding of the Pericyte Proteoglycan NG2
por: Schultz, Nina, et al.
Publicado: (2014)

Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer’s disease
por: Schultz, Nina, et al.
Publicado: (2019)

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
por: Henjum, Kristi, et al.
Publicado: (2016)

Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease
por: Spotorno, Nicola, et al.
Publicado: (2022)

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
por: Palmqvist, Sebastian, et al.
Publicado: (2015)

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
por: Kvartsberg, Hlin, et al.
Publicado: (2015)

Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
por: Cullen, Nicholas C., et al.
Publicado: (2021)

The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer’s but Not Parkinson’s Disease or Dementia with Lewy Bodies
por: Wennström, Malin, et al.
Publicado: (2015)

Midlife Atherosclerosis and Development of Alzheimer or Vascular Dementia
por: Gustavsson, Anna‐Märta, et al.
Publicado: (2019)

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2022)

Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid, tau, and cognition
por: Cullen, Nicholas C., et al.
Publicado: (2021)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Association of CSF Aβ(38) Levels With Risk of Alzheimer Disease–Related Decline
por: Cullen, Nicholas, et al.
Publicado: (2022)

Time Perception in Prodromal Alzheimer's Dementia and in Prodromal Dementia With Lewy Bodies
por: Pai, Ming-Chyi, et al.
Publicado: (2021)

Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer’s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study
por: Palmqvist, Sebastian, et al.
Publicado: (2012)

β-Amyloid–Dependent and –Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
por: Kumar, Atul, et al.
Publicado: (2022)

Altered Extracellular Vesicle miRNA Profile in Prodromal Alzheimer’s Disease
por: Visconte, Caterina, et al.
Publicado: (2023)

Circulating monocytes from healthy individuals and COPD patients
por: Aldonyte, Ruta, et al.
Publicado: (2003)

Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease
por: Kumar, Atul, et al.
Publicado: (2021)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ribk09lh3fgfiputc5ni4lvdro